Boardroom Alpha
Boardroom Alpha
BG · Current Report (Form 8-K) · Filed March 17, 2026

Bunge Global SA — Current Report (Form 8-K)

Form
8-K
Filed
March 17, 2026
Period
Mar 17, 2026
Ticker
BG
Accession
0001104659-26-029042
Boardroom Alpha · Filing insights

Bunge Global SA completed its acquisition of Viterra Limited on July 2, 2025, and provides financials and pro forma information.

About Bunge Global SA
Market cap
$21.4B
1Y TSR
+38.1%
3Y TSR
+2.4%
Board grade
C+
Sector
Consumer Defensive
CEO
Gregory A Heckman
Last annual meeting: May 20, 2026 · View full Bunge Global SA profile →

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington D.C., 20549

 

Form 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): March 17, 2026

 

BUNGE GLOBAL SA

(Exact name of registrant as specified in its charter)

 

Switzerland 000-56607 98-1743397
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(I.R.S. Employer
Identification No.)

 

Route de Florissant 13,  
1206 Geneva, Switzerland N/A

(Address of registered office and principal executive offices)

(Zip Code)

 

1391 Timberlake Manor Parkway 63017
Chesterfield, MO (Zip Code)

(Address of corporate headquarters)

  

 

(314) 292-2000

(Registrant’s telephone number, including area code)

 

N/A

(Former name or former address, if changed since last report)

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading Symbol(s)

 

Name of each exchange on which registered

Registered Shares, par value $0.01 per share   BG   New York Stock Exchange

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

¨ Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

 

Item 8.01.Other Events.

 

As previously announced, on July 2, 2025, Bunge Global SA (the “Company”) completed the acquisition of Viterra Limited (“Viterra”) in a stock and cash transaction pursuant to the definitive business combination agreement entered into by Bunge Limited, Viterra and its shareholders, including certain affiliates of Glencore PLC, Canada Pension Plan Investment Board, and British Columbia Investment Management Corporation.

 

This Current Report on Form 8-K is being filed to provide the financial statements and pro forma information referred to in Item 9.01 of Form 8-K.

 

Item 9.01.Financial Statements and Exhibits.

 

(a)Financial statements of business acquired.

 

The unaudited condensed consolidated statements of income, comprehensive income, financial position, cash flows, and changes in equity as of and for the six months ended June 30, 2025 of Viterra Limited S.a.r.l. are filed herewith as Exhibit 99.1 and are incorporated by reference into this item 9.01(a).

 

(b)Pro forma financial information.

 

The unaudited pro forma condensed combined financial information for the year ended December 31, 2025 are filed herewith as Exhibit 99.2 and incorporated by reference into this item 9.01(b).

 

(d)Exhibits.

 

Exhibit Description
   
99.1 Unaudited condensed consolidated statements of income, comprehensive income, financial position, cash flows, and changes in equity as of and for the six months ended June 30, 2025 of Viterra Limited S.a.r.l.
   
99.2 Unaudited pro forma condensed combined financial information for the year ended December 31, 2025
   
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: March 17, 2026

 

  BUNGE GLOBAL SA
   
  By /s/ Lisa Ware-Alexander  
    Lisa Ware-Alexander
    Secretary

 

 

 

From this filing to the file

Every SEC filing, parsed structured.

Boardroom Alpha indexes every 8-K, 10-K, 10-Q, and proxy back to 2000 — vote tabulations, comp tables, red flags, insider transactions, all queryable the day they hit EDGAR.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Bunge Global SA (BG)

Reference

Frequently asked questions

When did Bunge Global SA file this 8-K?
Bunge Global SA (BG) filed this Current Report (Form 8-K) with the SEC on March 17, 2026. The accession number assigned by EDGAR is 0001104659-26-029042.
What does an 8-K disclose?
Form 8-K is the SEC's current-report form, used to disclose material events between periodic reports (10-K / 10-Q). Triggers include CEO/CFO departures, acquisitions, bankruptcies, earnings releases, auditor changes, changes in fiscal year, and amendments to corporate governance. Each 8-K is keyed to one or more Item numbers (1.01 through 9.01).
What is the key takeaway from this filing?
Bunge Global SA completed its acquisition of Viterra Limited on July 2, 2025, and provides financials and pro forma information. This is Boardroom Alpha's one-line summary of the current report; see the full filing text above for the formal disclosure.
What Item codes does an 8-K cover?
An 8-K's Item codes (1.01 through 9.01) specify what kind of event is being disclosed — e.g. Item 1.01 for entering a material agreement, Item 5.02 for departure/election of directors and executive officers, Item 8.01 for other events. The Item codes for this 8-K appear in the filing text above.
Where can I find Bunge Global SA's prior current reports on EDGAR?
The SEC EDGAR browser lists every 8-K Bunge Global SA has filed under CIK 1996862, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer